BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 30138622)

  • 21. Conjugation of platinum(IV) complexes with chlorambucil to overcome cisplatin resistance via a "joint action" mode toward DNA.
    Qin X; Fang L; Chen F; Gou S
    Eur J Med Chem; 2017 Sep; 137():167-175. PubMed ID: 28586717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dinuclear platinum anticancer complexes with fluorescent N,N'-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles.
    Kalayda GV; Jansen BA; Wielaard P; Tanke HJ; Reedijk J
    J Biol Inorg Chem; 2005 May; 10(3):305-15. PubMed ID: 15824924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
    Zhu H; Yun F; Shi X; Wang D
    Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chk1 Inhibitor SCH900776 Effectively Potentiates the Cytotoxic Effects of Platinum-Based Chemotherapeutic Drugs in Human Colon Cancer Cells.
    Herůdková J; Paruch K; Khirsariya P; Souček K; Krkoška M; Vondálová Blanářová O; Sova P; Kozubík A; Hyršlová Vaculová A
    Neoplasia; 2017 Oct; 19(10):830-841. PubMed ID: 28888100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cisplatin and platinum drugs at the molecular level. (Review).
    Boulikas T; Vougiouka M
    Oncol Rep; 2003; 10(6):1663-82. PubMed ID: 14534679
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
    Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
    Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergistic antitumor effect of ginsenoside Rg3 and cisplatin in cisplatin‑resistant bladder tumor cell line.
    Lee YJ; Lee S; Ho JN; Byun SS; Hong SK; Lee SE; Lee E
    Oncol Rep; 2014 Nov; 32(5):1803-8. PubMed ID: 25175462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
    Wang Z; Xu Z; Zhu G
    Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
    Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
    Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential expression of collateral sensitivity or resistance to cisplatin in human bladder carcinoma cell lines pre-exposed in vitro to either X-irradiation or cisplatin.
    Bedford P; Shellard SA; Walker MC; Whelan RD; Masters JR; Hill BT
    Int J Cancer; 1987 Nov; 40(5):681-6. PubMed ID: 3679594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Study of the Mode of Action of Clinically Approved Platinum-Based Chemotherapeutics.
    Schoch S; Gajewski S; Rothfuß J; Hartwig A; Köberle B
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32967255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines.
    Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C
    Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1/2.
    Park BH; Lim JE; Jeon HG; Seo SI; Lee HM; Choi HY; Jeon SS; Jeong BC
    Oncotarget; 2016 Sep; 7(39):63870-63886. PubMed ID: 27564099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overcoming cisplatin resistance using gold(III) mimics: anticancer activity of novel gold(III) polypyridyl complexes.
    Palanichamy K; Sreejayan N; Ontko AC
    J Inorg Biochem; 2012 Jan; 106(1):32-42. PubMed ID: 22112837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: hypersensitivity of p53-mutant human tumour xenografts.
    Pratesi G; Perego P; Polizzi D; Righetti SC; Supino R; Caserini C; Manzotti C; Giuliani FC; Pezzoni G; Tognella S; Spinelli S; Farrell N; Zunino F
    Br J Cancer; 1999 Aug; 80(12):1912-9. PubMed ID: 10471039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic effects of pyrrolidine dithiocarbamate in small-cell lung cancer cells, alone and in combination with cisplatin.
    Tahata S; Yuan B; Kikuchi H; Takagi N; Hirano T; Toyoda H
    Int J Oncol; 2014 Oct; 45(4):1749-59. PubMed ID: 25070243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.